Thursday, October 15, 2026

Dollar Hits 2022 Low as Euro Surges 14%, Pound Faces $1.30 Break

The Bloomberg Dollar Spot Index fell to its lowest level since 2022, with the euro gaining 14% against USD in 2025. The British pound rose 7% year-to-date but recently dropped to €1.13, its weakest since April 2023, with analysts forecasting a decline below $1.30.

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
Dollar Hits 2022 Low as Euro Surges 14%, Pound Faces $1.30 Break
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The US dollar sank to its lowest point since 2022, with the Bloomberg Dollar Spot Index posting material declines against major currencies. The euro jumped 14% versus the dollar in 2025, while the British pound gained 7% over the same period.

Recent pressure pushed GBP/EUR to €1.13, the pound's weakest level since April 2023. Jordan Rochester at Mizuho Bank forecasts the pound could fall below $1.30 as the currency realignment deepens. The pound traded at $1.3086 this week, down 0.5%.

For international banks, the dollar's weakness reshapes currency hedging strategies and cross-border lending costs. European exporters gain pricing power in dollar-denominated markets, while US multinationals face margin pressure on overseas earnings when converted back to stronger local currencies.

Investment flows are shifting as currency movements alter relative returns. A 14% euro gain against the dollar means euro-zone assets delivered that additional return to US investors before any underlying performance. British investors holding European assets saw opposite effects, with the pound's slide to €1.13 eroding returns.

Safe-haven demand drove flows into the Swiss franc amid systemic uncertainty. The franc's appreciation reflects investor concerns about the sustainability of current currency trends and underlying economic divergences between regions.

Corporate finance teams are recalibrating strategies. Companies with dollar debt but euro or pound revenues see natural hedges strengthen. Conversely, firms with reversed exposures face widening currency mismatches that pressure balance sheets and debt servicing costs.

The currency realignment stems from diverging monetary policy expectations and economic growth trajectories. European markets showed strength, with the Stoxx 600 hitting a record 583.4 points. UK gilts saw record demand, with £69 billion in bids for £4.25 billion of inflation-linked bonds.

Simon Phillips at No1 Currency noted continued pressure on the pound despite its year-to-date gains. Market positioning suggests traders expect further dollar weakness, though the pace and duration remain uncertain.

Banking relationships across borders face repricing as currency volatility increases transaction costs and hedging expenses. International lending spreads are adjusting to reflect currency risk premiums that have widened materially since the dollar began its decline.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com